Taken together, given the effectiveness of PDE inhibitors in restricting YAP/TAZ oncogenic activities, PDE inhibitors in combination with other medicines could potentially offer advanced anti-cancer strategies. The gene discussed is ALDH7A1; the disease is cancer.